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Abstract
Objective—Purine enzyme activities may 
predict the effectiveness of azathioprine 
treatment and be associated with 
increased deaths from infectious diseases. 
In rheumatoid arthritis, patients show 
variable responses to azathioprine and a 
higher percentage of death is caused by 
infections. The aim of the study was to 
investigate possible rheumatoid arthritis 
associated abnormalities o f purine en­
zyme activities by measuring several of 
these enzymes in patients with recent 
onset rheumatoid arthritis before treat­
ment with disease modifying antirheu­
matic drugs or prednisone.
Methods—23 patients with recent onset 
rheumatoid arthritis and 28 healthy con­
trols were studied. Activities of the en­
zymes S’-nucleotidase, purine nucleoside 
phosphorylase (PNP), hypoxanthine gua­
nine phosphoribosyltransferase (HGPRT), 
and thiopurine methyltransferase (TPMT) 
were measured. Assessment of disease 
activity and blood sampling for routine 
measurements and HLA typing were done 
simultaneously.
Results—Purine enzyme activities did not 
differ between patients and healthy 
controls. Enzyme activities had no signifi­
cant relations with indices of disease 
activity or rheumatoid factor titre or with 
the rheumatoid arthritis associated HLA 
types. Activity of 5'nucleotidase decreased 
with age (P < 0.05) and was lower by about 
27% (P = 0.007) in males than in females. 
Conclusions—In rheumatoid arthritis pa­
tients, neither the variability in azathio­
prine effectiveness nor the increased death 
rate from infections can be explained by 
pre-existing abnormalities in the activities 
of the purine enzymes 5’-nucleotidase,
PNP, HGPRT, or TPMT at an early stage
of the disease, before disease modifying 
antirheumatic drugs or prednisone treat­
ment. Besides adjustment for age, results 
of studies involving purine 5’nucleotidase 
activity should also be adjusted for sex.
(Ann Rheum Dis 1996;55:733-738)
Azathioprine is used in the treatment of immu-
diseases and to prevent graft 
rejection in transplant recipients. After 
ingestion the drug is rapidly converted to 
6-mercaptopurinc (6-MP), a drug which is 
used in die treatment of leukaemia. 6-MP is a 
substrate in three metabolic pathways1: catabo­
lism to 6-thiouric acid by xanthine oxidase, 
methylation to methylmercaptopurine metabo­
lites by thiopurine methyltransferase (TPMT), 
and conversion by hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) to 6-thio- 
inosine-monophosphate which consequently 
results in formation of cytotoxic 6-thioguanine 
nucleotides2 (figure )
Rheumatoid arthritis patient« treated with 
azathioprine show variable responses ranging 
from successful reduction of disease activity to 
occurrence of side effects like leucopenia, pan­
cytopenia, gastrointestinal complaints, hepato- 
toxicity, or hypersensitivity. *,}
Nowadays four different enzyme distur­
bances are known to be related to the effect of 
azathioprine treatment. Patients with the 
Lesch-Nyhan syndrome (inborn HGPRT defi­
ciency) are resistant to azathioprine,u and per­
sons with T PM T  deficiency11 n or low activity 
of purine 5'nucleotidase1' n arc prone to 
develop bone marrow toxicity. Finally the 
simultaneous use of azathioprine and allopuri- 
nol, a competitive inhibitor of xanthine 
oxidase, increases toxicity of azathioprine so 
that the dosage of azathioprine has to be 
reduced to approximately 25%,'
Rheumatoid arthritis may be connected to 
purine metabolism not only by the use of aza­
thioprine but also by the disease itself since it 
involves at very least a dysregulation of the 
immune system, expressed by autoimmunity 
and changes in lymphocyte subsets.1'4 In 
rheumatoid arthritis, there is probably also a 
deficiency of the immune system» since it has 
been established that death due to infectious
1  A i occurs more oiten in t' n
arthritis patients than in the general 
population. * Early death due to infection is a 
well known consequence of a number of 
immune deficiency syndromes* which in turn 
are related to purine enzyme deficiencies, for 
example T  lymphocyte malfunction due to
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deficiency of purine nucleoside phosphorylase 
(PN P)18 1,J and (adult onset) primary hypogam- 
maglobulinaemia and combined immunodefi­
ciency due to deficiency of 5Lnucleotidase.~031
Despite the fact that there are no previous 
data showing that subtle changes in enzyme 
levels have an impact on azathioprine effective­
ness or susceptibility to infections, the above 
mentioned observations still raise the question 
of whether the purine enzymatic make up in 
rheumatoid arthritis patients is also different. 
In addition, it would be very useful if purine 
enzyme activities could give some prediction 
about the outcome of azathioprine treatment.
As far as we know there are only two reports 
addressing differences between rheumatoid 
arthritis patients and healthy controls, one of 
which is a recent pilot study from our own 
group, showing differences in purine enzyme 
activities of 51-nucleotidase and PNP,22 the 
other showing differences in 5 -nucleotidase 
and adenosine deaminase activity.2* The differ­
ence between these studies and the one 
presented here is that the first studies were
done in rather heterogeneous groups of
The influence of different disease 
modifying antirheumatic drugs, prednisone, 
other medications, duration of the disease, age, 
and sex could not be excluded.
To detect possible differences present at the 
beginning of the disease (rheumatoid artiiritis 
associated) and to obviate several confounding 
variables from the two previous reports, we 
have studied a homogeneous group of rheuma­
toid arthritis patients within the first year of 
diagnosis and before treatment with a disease 
modifying antirheumatic drug or prednisone.
The study protocol was approved by the eth­
ics committee of the hospital.
Methods
PATIENTS AND CONTROLS
In the period from February 1993 to April 
1994, 23 rheumatoid arthritis patients and 28 
healthy controls entered the study. They were 
all Caucasian* Patients had to meet die follow­
ing criteria: the 1987 ARA criteria/ 4 disease 
duration less than one year and no previous 
treatment with disease modifying antirheu­
matic drugs or prednisone. The use of 
non-steroidal antiinflammatory drugs (NSAID) 
or paracetamol was allowed. Patients with 
other coexisting diseases were excluded, as 
were persons using allopurinol.
To avoid influences of possible circadian 
rhythms, clinical assessments and blood 
sampling were done between 9 and 11 am for 
all participants.
CLINICAL ASSESSMENTS
Indices of disease activity included patients 
assessments of pain and general health (GH) 
on visual analogue scales (VAS) of 10 cm (0 = 
best possible, 10 = worst possible), the Ritchie 
articular index (RAI), the number of swollen 
joints, and the degree of morning stiffness. The 
disease activity score (DAS4)2,5 was calculated 
by using the RAI, the number of swollen joints, 
the VAS-GH, and the erythrocyte sedimenta­
tion rate (ESR).
LABORATORY ASSESSMENTS
Venous blood samples for determination of 
purine enzyme activities, IgM-RF (e l is a , posi­
tive if > 10 IU ml'1), HLA types, and routine 
blood tests (patients only) were collected 
immediately after the clinical assessments. 
Routine blood analyses included haematologi- 
cal and biochemical profiles, serum uric acid, 
the ESR (Westergren, mm in 1 h), and 
C-reactive protein (mg ml*1). Tissue typing of 
all patients for HLA class I and II (DR/DQ) 
was performed by standard techniques.
To determine purine enzyme activities of 
5 -nucleotidase, PNP, and HGPRT, blood was 
collected in 10 ml Vacutainer tubes containing 
polystyrene granules (Becton and Dickinson). 
Mononuclear cells were obtained by Ficoll- 
Isopaque (density 1.077 g ml'1, Nycomed) 
gradient centrifugation of defibrinated blood 
and in these cells the enzyme activities were 
measured by a new high performance liquid 
chromatography m e th o d .E n zy m e  activities
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are expressed in nmol 10"(1 mononuclear cells 
hf1 of incubation. To measure the TPM T activ­
ity in red cell lysate as described by 
Weinshilboum et al?1 peripheral blood was col­
lected in 10 ml Monoject tubes containing 150 
USP units of lithium heparin (Sherwood 
Medical). TPM T activity is expressed in pmol 
10 ’° erythrocytes h"1 of incubation,
AU enzyme assays were carried out in quad­
ruplicate.
Table 1 Characteristics o f patients and controls, Values are 
mean (SD )
STATISTICAL ANALYSIS
Pearson’s correlation analyses were used to 
study relations between purine enzyme 
activities and indices of disease activity, 
between indices of disease activity and age* and 
between enzyme activities and rheumatoid fac­
tor. Since the distributions of 5-nucleotidase 
(patients and controls) and HGPRT (patients) 
were not quite normal, Spearman’s rank corre­
lation analyses were also performed. Two sam­
ple Student t tests were used to compare 
enzyme activities in HLA positive and HLA 
negative patients (and additionally Mann- 
Whitney tests with respect to 5'-nucleotidase 
and HGPRT), Influence of age on enzyme 
activities was analysed by linear regression 
analysis. Differences between patients and 
healthy controls and between the two sexes 
with respect to enzyme activities (and 
additionally with respect to the square root of 
S’-nucleotidase) were examined by a two way 
analysis of covariance adjusting for age.
The statistics were processed by SAS 
computer software (SAS Institute, Cary, NC, 
USA) and by NCSS computer software 
(version 5,1, 1988, Dr J L  Hintze, North Kay- 
sville, Utah, USA). Test results were 
considered to be significant at P £ 0.05.
RA patients 
(ti -23) Controls (n—2H)
Age in years [range] 54.0 (14.0) 43.6 (10.4)
[23 to 73] [26 to 63]
Male/female (n) 13/10 11/17
Disease duration in 4.3 (3.5)
months [range] [1 to 12]
RF positive patients (n) 
Disease activity indices
20
ESR (Westergren) 31.2 (22.4)
Ritchic articular index 11.8(0.7)
No of swollen joints 16.3(9.2)
VAS general health 42.0 (23.5)
DAS,,
HLA type; 
positive/negative (n)
4,1 (1.3)
DR1 5/15
DR2 2/18
DR3 6/14
DR4 10/9
RA, rheumatoid arthritis; RF, rheumatoid factor> HSR, 
erythrocyte sedimentation rate; VAS, visunl Analogue scnle; 
DAS,„ disease activity score; HLA, human lymphocyte 
antigen.
-0 .34  to 0,46. None of these correlation coef­
ficients reached significance except the one 
between 5'nucleotidase activity and ESR. 
However, checking the latter correlation by a 
Spearman analysis, which in this case is 
probably better in view of the not quite normal 
distribution, no significance was found. 
Furthermore, no relevant correlations were 
found between indices of disease activity and 
age. A relation between the rheumatoid factor 
titre and the activity of the tested enzymes 
could not be demonstrated (data not shown).
Enzyme activities in HLA positive and HLA 
negative patients were examined for HLA-
D R 1 , HLA-DR2 , HLA-DR3, and HLA-DR4,
There were no differences (data not shown).
Results
STUDY POPULATION
Characteristics of patients and healthy controls 
are given in table 1. All patients had normal 
laboratory values for kidney and liver function 
and a normal serum urate. Only minor abnor­
malities were found in haematological variables 
(low haemoglobin concentration, raised 
platelet count) and were considered to be 
attributable to activity of the disease (data not 
shown).
ENZYME ACTIVITY— INFLUENCE OF AGE
In rheumatoid arthritis patients as well as in 
healthy controls only 5 -nucleotidase activity 
showed a significant decrease with increase of 
age (P = 0.05 and P = 0.009 respectively) 
(table 3). The estimates of the yearly decrease 
ranges from 0,21 nmol 10"“ cells lv1 in rheuma­
toid arthritis patients to 0.37 nmol 100 ceils h“1 
in the healthy controls.
REIATIONS BIT I’WEEN ENZYME ACTIVITY, DISEASE 
ACTIVITY, RHEUMATOID I?ACTOR, AND HLA TYPE
Pearson’s coefficients of correlation for the 
relations between enzyme activities and the 
indices of disease activity (including the D A SJ 
are presented in table 2 . They varied from
Table 3 Linear regression analysis results for examining the influence o f age on purine 
enzyme activity. Estimates show the yearly change in enzyme activity
Early RA patients Healthy controls
y  N T PNP HGPRT TPMT S'N T PNP HGPRT TPM T
Estimate -0.21 1.1 0.06 0.02 -0.37 0.7 0.08 0.08
SE 0.10 0.8 0.05 0.06 0.13 1.0 0.13 0.09
P value 0.05 0.22 0.26 0.74 0.009 0.51 0.55 0.36
RA, rheumatoid arthritis. Other abbreviations, see legend to table 2.
SE, standard error of the estimate; enzyme activities of 5'NT, PNP and HGPRT are expressed 
in nmol 10"6 cells h f1 of incubation; TPM T activity in pmol 1(TA cells h“1 of incubation.
Table 2 Coefficients o f correlation according to Pearson 
(and Spearman) between indices o f disease activity and 
purine enzyme activity and between indices o f disease 
activity and age in rheumatoid arthritis patients
* * * * * * i m
Swollen
RAI jts No ESR VAS-GH DASj
5'NT “0.02 0.25 0.46 0,26 0.22
(0 .1 2 ) (0,15) (0,37)* (0.19) (0 .10)
PNP 0.25 0,05 0.29 0.13 0.05
HGPRT* »0.19 0.22 -0.02 0,001 0.16
(«0.10) (0 .2 1 ) (0.07) (0.09) ( 0.01)
TPM T •0.33 0,34 0.20 0.10 0,27
Age 0.02 -0.05 0.04 0.23 0,01
RAI, Ritchie articular index; ESR, erythrocyte sediment«don 
rate, DAS*, disease activity score; Swollen jts No, number of 
swollen joints; VAS-GH, visual analogue scale general health; 
5’NT, S'-nucleotidase; PNP, purine nucleoside phosphorylane; 
HGPRT, hypoxanthine guanine phosphoribosyltransferasci 
TPMT» thlopurinc methyl transferase.
* Critical value (n=23) for Pearson (and Spearman): 0,41 
(0.42);a n*22.
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■INKLUBNCES OF GROUP, SKX,ENZYME ACTIVITY—
AND AGE
Results of the two way analysis of covariance 
examining the influences of group, sex, and age 
on enzyme activities are shown in the tables 4 
and 5, No significant differences between 
rheumatoid arthritis patients and controls, 
averaged over both sexes, could be established. 
Interaction tests showed that mean patient- 
control differences were not clearly different in 
the two sexes.
Males showed a significant lower (P <
0.007) mean 5'~nucleotidase activity than 
females (averaged over both groups: ±4 activity 
units or 27% lower activity). Mean male 
S'-nucleotidase activity was 80% and 68% of 
the female activity respectively for the rheuma­
toid arthritis group and the control group.
A significant (P = 0.005) decrease of 
S'-micleotidase activity with age was again 
found. This decrease amounted about 0,23 
activity units per year. Activities of PNP and 
H G PR T showed a tendency to increase with 
age (P = 0.10 and P = 0.07, respectively) about
1.1 and 0.09 activity units per year, 
respectively. (For 5'-nucleotidase activity., simi­
lar results were found after a square root trans­
formation.)
Table 5 Testing results (P  values) from tzuo way analyses 
of covariance examining the influence of group and sex on 
purine enzyme activités with age as covariable
Discussion
Our previous pilot study indicates that 
activities of some purine enzymes in 
rheumatoid arthritis differ from those in 
healthy controls and are associated with the 
outcome of azathioprine treatment, whereas 
there is no clear relation between enzyme 
activity and disease activity,22 However, die 
group of patients in that study is heterogeneous 
and the influence of disease modifying 
antirheumatic drugs, prednisone, other 
medications, disease duration, age, and sex 
cannot be excluded. It was to determine if the 
differences in enzyme activities between 
rheumatoid arthritis and controls are related to 
the disease itself, the drugs used, or other con­
founding variables tiiat we started the present 
study. In contrast to the other studies,22 21 the 
enzyme activities are measured solely in recent 
onset rheumatoid ardiritis patients not 
previously treated with a disease modifying 
antirheumatic drug or prednisone.
One of the pitfalls may be that enzyme activ­
ity reflects disease activ ity .O ur tests are reas-
7able 4 Ad.justed least squares means (with standard 
errors) fo r  enzyme activities, classified by patient-control 
status and sex on the basis of a two way analysis of 
covariance model at a mean age o f 48,3 years
Male Female
5'N T RA 15.6 (1.9) 19.6 (2.0)
Controls 13.7 (1.9) 20,4 (1.6)
PNP RA 199 (16) 219 (17)
Controls 201 (16) 223 (14)
HGPRT RA 9.0 (1.1) 12.0 (1.1)
Controls 12.3 (1.6) 12.2 (1.1)
T P M T RA 22.3 (1.3) 24.9 (1.3)
Controls 23.0 (1.3) 21.5 (1.1)
RA, rheumatoid arthritis, Other abréviations, sec legend ta 
table 2.
The male/female numbers for patienta and controls arc 13/10 
and 11/17> respectively, except for the HGPRT activity with 
ratios of 12/10 and 5/11.
5'N T PNP HGPRT TPMT
Group 0.78 0.86 0.34 0.31
Sex 0.007 0.18 0.13 0.67
Age 0,005 0.10 0.07 0,31
Group/sex 0.48 0.94 0.11 0.10
interaction
Abbreviations, see legend to table 2.
2 0
suring on this issue. Most correlation 
coefficients show little or no relation between 
enzyme activities and indices of disease 
activity.
In accordance with a previous study,
5'-nucleotidase activity is significantly age 
dependent, showing decreasing values with 
increasing age. The degree of change is 
comparable for patients and controls. A 
combined analysis with adjustment for sex 
does not change this finding. It may be that age 
is also a factor influencing PNP and HGPRT 
activities. Although die change was not signifi­
cant, bo til enzyme activities tended to increase 
with age.
Activity of 5 -nucleotidase is also subject to a 
substantial influence of sex and as far as we 
know this has not been reported before. A 
combined analysis of patients and controls 
with adjustment for age shows a 27% lower 
5-nucleotidase activity in males than in 
females. The underlying mechanism is not 
known but the difference in hormonal status 
may possibly play a role.
Susceptibility, prognosis, and clinical course 
of rheumatoid arthritis are related to the rheu­
matoid factor status and some I-ILA types. 51' 12 
We could not show a clear correlation between 
enzyme activities and rheumatoid factor titre3 
nor did we find differences in enzyme activities 
between positive and negative groups of the 
HLA types D R 1 , DR2, DR3, and DR4.
In contrast to previous reports,22 2i we did 
not find any difference in purine enzyme 
activities between patients with early 
rheumatoid arthritis and controls. Confound­
ing variables like age, sex, duration of the 
disease, and medication (disease modifying 
antirheumatic drugs, prednisone, others) are 
avoided by means of the study design and sta­
tistical analysis. All of our patients used 
NSAID and a few used paracetamol. Only two 
patients used co-medication by inhalation for 
chronic obstructive pulmonary disease. Their 
enzyme activities were well within the ranges of 
the other patients. This means that the only 
important differences between patients and 
controls are the use of NSAID and the 
presence of rheumatoid ardiritis. To our 
knowledge, nodiing is known about the 
influence of NSAID on 5-nucleotidase, PNP, 
or HGPRT activities. More is known about 
NSAID and red blood cell TPM T activity. 
One report mentions a gender difference11 
while others do not.5'1 ™ The same report 
shows that chronic disease in general is associ­
ated with somewhat higher TPM T levels and 
that NSAID are associated with lower levels of 
TPMT. Although a gender difference was not
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found in our study, the possibility that opposite 
influences of NSAID and chronic disease mask 
a difference with healthy controls cannot be 
entirely excluded. However, based on our 
results we conclude, with some reservation 
about TPM T activity, that the variability in 
response to azathioprine treatment and the 
increased death rate from infectious diseases 
cannot be explained by pre-existing (rheuma­
toid arthritis associated) differences in the 
enzyme activities tested.
The previous reports about rheumatoid 
arthritis patients, as we mentioned above, were 
based on patient groups characterised by 
heterogeneity in disease duration and 
medication. In addition» the enzyme activities 
were determined by different enzyme assays, 
the type of 5 -nucleotidase investigated differed 
(membrane bound S'-nucleotidase" versus 
total S'-nucleotidase (ectoplasmic and cyto­
plasmic S'-nucleotidase),22 and in neither 
report were enzyme activities adjusted for age 
and sex. For these reasons a comparison of 
previous data and the data presented in this 
study is hardly possible. Furthermore, it is 
known that activities of some purine enzymes 
are not evenly distributed among the several 
mononuclear cells or cell types36 37 or different 
stages of maturation,3H and that with age 
percentile changes occur in lymphocyte 
subsets and maturity.w It is conceivable that 
age, disease duration, or disease modifying 
antirheumatic drug use may cause a shift in the 
subtype or maturity of peripheral blood mono­
nuclear cells, and that different disease 
modifying antirheumatic drugs may have 
different induction effects on enzyme activities. 
Further analyses of these assumptions are 
needed and some are under investigation now.
In summary, no differences were found in 
purine enzyme activities of S'-nucleotidase, 
PNP, HGPRT, or T PM T  between patients 
with early rheumatoid arthritis before disease 
modifying antirheumatic drug or prednisone 
treatment and healthy controls. The tested 
enzyme activities have no associations with dis­
ease activity, nor with the rheumatoid factor 
litre* nor with the rheumatoid arthritis 
associated H IA  types. Our study confirms the 
significant decrease of 5'nucleotidase activity 
with age. It also shows a tendency, although 
not significant, towards increasing activities of 
PNP and HGPRT with age. A new finding is 
that 5-nucleotidase activity in males is about 
27% lower than in females.
In future studies, enzyme activity of 
5-nucleotidase should be adjusted both for age 
and sex, and studies on activities of PNP and 
HGPRT should be evaluated for possible 
influences of age.
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